Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 12/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779299 | 0.80 | PIN1 (0.47) | PIN1MEN1KMT2AGSK3BALDH1A1 | |
| SCHEMBL17110527 | 0.78 | CKS1B (0.38) | ALDH1A1CKS1BSKP1SKP2MAPT | |
| SCHEMBL17110470 | 0.78 | PIN1 (0.47) | PIN1MEN1KMT2AGSK3BALDH1A1 | |
| SCHEMBL11903190 | 0.70 | KMT2A (0.48) | PIN1MEN1KMT2AGSK3BALDH1A1 | |
| SCHEMBL27538176 | 0.70 | ADORA1 (0.50) | PIN1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL31434441 | 0.68 | NPC1 (0.51) | MEN1KMT2AALDH1A1TDP1MAPT | |
| SCHEMBL1200414 | 0.66 | MEN1 (0.41) | MEN1KMT2AGABRA5MAPT | |
| SCHEMBL6617821 | 0.64 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL1201342 | 0.64 | ALDH1A1 (0.38) | PIN1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL14809766 | 0.63 | PIN1 (0.54) | PIN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3122346-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148344-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143654-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | PIN1 1271/4885MEN1 4696/4885KMT2A 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.